Review of Adherence to Medications for the Treatment of Osteoporosis

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2006 Mar 11

PMID 16527004

Citations 18

Authors

Deborah T Gold

Stuart Silverman

Affiliations

Soon will be listed here.

Abstract

One of the major challenges of successful osteoporosis management is poor patient adherence to current therapies. Individuals who are nonadherent have significant consequences of reduced bone mineral density response, reduced bone marker suppression, and increased risk for fracture compared with individuals who are adherent. Although reducing the dosing interval from daily to weekly oral bisphosphonates has improved adherence, adherence with weekly bisphosphonates remains suboptimal. Barriers to adherence include patient health beliefs, inadequate patient education and age. Potential solutions include increased health care provider-patient interaction, and longer times between doses of medications.

Citing Articles

Predictors of discontinuation of osteoporosis treatment: sub-analysis of the Japanese osteoporosis intervention trial-05 (JOINT-05).

Takeuchi Y, Nakatsuka Y, Tanaka S, Kuroda T, Hagino H, Mori S J Bone Miner Metab. 2024; 42(6):675-680.

PMID: 39141119 PMC: 11632025. DOI: 10.1007/s00774-024-01541-3.

Impact of Medication Adherence on Bone Mineral Density and Fracture Risk in Patients With Osteoporosis: A Systematic Review.

Alahmari M, AlHilali A, Thabet T, Alshahrani M, Mobasher W, Al Mubarak D Cureus. 2023; 15(7):e42115.

PMID: 37602050 PMC: 10436998. DOI: 10.7759/cureus.42115.

Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.

Singer A, Liu J, Yan H, Stad R, Gandra S, Yehoshua A Osteoporos Int. 2021; 32(12):2473-2484.

PMID: 34095966 PMC: 8608759. DOI: 10.1007/s00198-021-05951-1.

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and....

Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, Al-Daghri N, Biver E Osteoporos Int. 2019; 30(11):2155-2165.

PMID: 31388696 PMC: 6811382. DOI: 10.1007/s00198-019-05104-5.

Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications?.

Silverman S, Gold D Curr Osteoporos Rep. 2018; 16(6):772-774.

PMID: 30374627 DOI: 10.1007/s11914-018-0494-0.

References

Yood R, Emani S, Reed J, Lewis B, Charpentier M, Lydick E . Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003; 14(12):965-8. DOI: 10.1007/s00198-003-1502-4. View

Solomon D, Avorn J, Katz J, Finkelstein J, Arnold M, Polinski J . Compliance with osteoporosis medications. Arch Intern Med. 2005; 165(20):2414-9. DOI: 10.1001/archinte.165.20.2414. View

Tosteson A, Grove M, Hammond C, Moncur M, Ray G, Hebert G . Early discontinuation of treatment for osteoporosis. Am J Med. 2003; 115(3):209-16. DOI: 10.1016/s0002-9343(03)00362-0. View

Turbi C, Herrero-Beaumont G, Acebes J, Torrijos A, Grana J, Miguelez R . Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther. 2004; 26(2):245-56. DOI: 10.1016/s0149-2918(04)90023-9. View

Miller N . Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997; 102(2A):43-9. DOI: 10.1016/s0002-9343(97)00467-1. View

McCombs J, Thiebaud P, McLaughlin-Miley C, Shi J . Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004; 48(3):271-87. DOI: 10.1016/j.maturitas.2004.02.005. View

Pickney C, Arnason J . Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int. 2005; 16(9):1156-60. DOI: 10.1007/s00198-004-1818-8. View

Siris E, Harris S, Rosen C, Barr C, Arvesen J, Abbott T . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81(8):1013-22. DOI: 10.4065/81.8.1013. View

Berg J, Dischler J, Wagner D, Raia J . Medication compliance: a healthcare problem. Ann Pharmacother. 1993; 27(9 Suppl):S1-24. View

10.

Claxton A, Cramer J, Pierce C . A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-310. DOI: 10.1016/s0149-2918(01)80109-0. View

11.

Caro J, Ishak K, Huybrechts K, Raggio G, Naujoks C . The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004; 15(12):1003-8. DOI: 10.1007/s00198-004-1652-z. View

12.

Clowes J, Peel N, Eastell R . The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004; 89(3):1117-23. DOI: 10.1210/jc.2003-030501. View

13.

Osterberg L, Blaschke T . Adherence to medication. N Engl J Med. 2005; 353(5):487-97. DOI: 10.1056/NEJMra050100. View

14.

OBrien M, Petrie K, RAEBURN J . Adherence to medication regimens: updating a complex medical issue. Med Care Rev. 1992; 49(4):435-54. DOI: 10.1177/002570879204900403. View

15.

Sclar D, Chin A, Skaer T, Okamoto M, Nakahiro R, Gill M . Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther. 1991; 13(4):489-95. View

16.

Sikka R, Xia F, Aubert R . Estimating medication persistency using administrative claims data. Am J Manag Care. 2005; 11(7):449-57. View

17.

Hart J . Commentary: Can health outputs of routine practice approach those of clinical trials?. Int J Epidemiol. 2002; 30(6):1263-7. DOI: 10.1093/ije/30.6.1263. View

18.

Col N, Fanale J, Kronholm P . The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990; 150(4):841-5. View

19.

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

20.

Bender B, Milgrom H, Rand C . Nonadherence in asthmatic patients: is there a solution to the problem?. Ann Allergy Asthma Immunol. 1997; 79(3):177-85; quiz 185-6. DOI: 10.1016/S1081-1206(10)63001-3. View